Arkolith/Insider Trading/CRVS/Form 4

Miller Richard A MD

President and CEO, DirectorCorvus Pharmaceuticals, Inc. (CRVS) · full profile →Form 4 · filed May 7, 2024
Net Buying
Open-Market Buys
$999K
Open-Market Sells
$0
Net Open-Market Flow
$999K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 6, 2024Buy(P)578K$1.73$999K578K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 6, 2024Buy(P)559K——559K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000231) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML